We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
PhRMA member companies invested a record
$38.8 billion in pharmaceutical R&D in 2004, an increase of nearly 13 percent
from the previous year, according to the association's annual membership survey.
U.S. drug industry representatives are applauding the approval of strict new
patent rules in India, but the action has been met with mixed reactions elsewhere,
including from international advocacy groups and within India's own drug industry.
Charles River Laboratories International, Inc. announced that it has called
for redemption all of its $185 million, 3.5 percent Senior Convertible Debentures
due Feb. 1, 2022.
Eisai Co. (4523.TO) said it has acquired the rights to develop, produce and
market Dainippon Pharmaceutical Co.'s (4506.TO) drug for epilepsy treatment
in Asia excluding Japan.
Teragenix Corporation has launched its Latin American Initiative. This plan
expands the company's already developed presence in South and Central America
as one of the largest CRO's in the region.
TolerRx, a biopharmaceutical company focused on the discovery, development,
and commercialization of novel therapies to treat patients with diseases of
the immune system, announced the completion of its Series D financing.
Ranbaxy Pharmaceuticals, a wholly owned subsidiary of Ranbaxy Laboratories (Ranbaxy),
announced that it successfully invalidated claims 1-3 (all claims sought to
be invalidated) of Austrian Patent No. AT E 207 896 as anticipated by, and as
lacking inventive step over, respectively, a Pfizer-owned published patent application
and a Pfizer owned patent, as reflected by a decision released by the Austrian
Patent Office.
Phytopharm announced that it has received confirmation from Yamanouchi Pharmaceutical
Co. that as a result of a portfolio review arising out of the merger of Yamanouchi
with Fujisawa Pharmaceutical Co., Yamanouchi is to terminate the licensing agreement,
covering Japan and some other Asian countries, in connection with Cogane (PYM50028),
Phytopharm's candidate product for the treatment of Alzheimer's disease.
Alnylam Pharmaceuticals, a leading RNAi therapeutics company, and Dowpharma,
a business unit of The Dow Chemical Company, announced an agreement for the
manufacture and supply of candidate RNAi therapeutics for Alnylam's lead development
programs in age-related macular degeneration and respiratory syncytial virus
infection.
Andrx Corporation announced that it has completed
its previously announced sale and licensing of certain rights and assets related
to its Fortamet and Altoprev brand pharmaceutical products to First Horizon
Pharmaceutical Corporation (First Horizon).